Prone positioning for peripherally inserted central catheter on a patient with anal cancer.
Prone positioning for peripherally inserted central catheter on a patient with anal cancer. J Vasc Access. 2019 Jun 24;:1129729819857024 Authors: Longo F, Costa F, Piliego C, Agrò FE Abstract Peripherally inserted central catheters are usually inserted in supine patients. What should we do when facing a patient who cannot tolerate this position? In this article, we are describing a particularly difficult patient: not only supine decubitus was intolerable to her but lying on the side was unbearable, too. That is why, to manage a patient who required a central access but could not tolerate the usual position for placing it, we tried to do that in prone position. PMID: 31232211 [PubMed - as supplied by publisher]
Publication date: Available online 19 August 2019Source: The American Journal of SurgeryAuthor(s): Katherine Bingmer, Asya Ofshteyn, David Dietz, Sharon L. Stein, Emily SteinhagenAbstractBackgroundImmunosuppressed patients have an increased risk of developing anal cancer, but little data exists regarding outcomes of this population.MethodsA retrospective review of anal cancer patients at a single academic institution from 2006-2017 was performed.Results19 (14%) of 136 anal cancer patients were immunosuppressed. Immunosuppressed patients were more likely to be hypoalbuminemic (21% vs. 6%, p=0.025), less likely to complete c...
ConclusionsOver half of anal cancer patients were initially misdiagnosed, and 25% were symptomatic for more than 6 months prior to diagnosis. Those patients diagnosed earlier tended to be more likely to receive complete chemoradiation therapy. We were unable to show a statistical difference in outcomes between groups. Further investigation into provider education and awareness of anal cancer is warranted to im prove the care of these patients.
To investigate the prognostic significance of positron emission tomography (PET) parameters from F-18 fluorodeoxyglucose (FDG) PET scans performed pre- and post- chemo-radiotherapy (CRT) for squamous cell carc...
AbstractStandardized terminology is critical to providing consistent reports to referring clinicians. This lexicon aims to provide a reference for terminology frequently used in rectal cancer and reflects the consensus of the Society of Abdominal Radiology Disease Focused Panel in Rectal cancer. This lexicon divided the terms into the following categories: primary tumor staging, nodal staging, treatment response, anal canal anatomy, general anatomy, and treatments.
Doublet chemotherapies are the mainstay in the management of metastatic anal cancer. Immunotherapy has been incorporated into guidelines in a refractory setting. Treatment options remain limited with tumor progression beyond immunotherapy. Modified docetaxel, cisplatin, and fluorouracil (mDCF) chemotherapy, after progression postimmunotherapy, has shown a near‐complete response in our patient with metastatic anal cancer. This likely is secondary to the sequence of immunotherapy followed by chemotherapy that is yielding greater than histo rical responses. AbstractDoublet chemotherapies are the mainstay in ...
CONCLUSIONS: Malignant tumorswere still the main cause of death in one's life time, giving rise to LDP. LDP caused by malignant tumours has twodivisions. First, traditional upper digestive system cancers related to long-term chronic infection, such as esophagealcancer, gastric cancer, and liver cancer, which has shown a significant downward trend. Second, lung and colorectalcancers related to the environmental factors and lifestyle, which are on the rise. PMID: 31350960 [PubMed - in process]
ConclusionsInfrared coagulation is a safe and effective method for ablation of high-grade anal dysplasia that could help prevent anal cancer. Continued surveillance is recommended due to the risk of recurrence.
Authors call for new screening strategies for anal cancer prevention in women living with HIV
In this study, we used electronic health record data from a single urban cancer center to identify patients from 2004-2018 with anal cancer who have also had a pre-initial treatment CEA measurement. We identified 40 patients who met our eligibility criteria. Of those, 11 (27.5%) had an elevated pretreatment CEA. Elevated CEA was not associated with any of the clinical or demographic covariates; however, three out of five patients with a recurrence had an elevated CEA. PMID: 31319725 [PubMed - as supplied by publisher]
CONCLUSIONS: In our population-based cohort of HIV-infected subjects with long-term follow-up, the risk of progression from anal intraepithelial neoplasia III to anal squamous cell carcinoma was higher than reported in other studies and was not associated with the receipt of anal intraepithelial neoplasia III treatment. See Video Abstract at http://links.lww.com/DCR/A933.